Publikasi Scopus 2024 per tanggal 30 September 2024 (820 artikel)

Publikasi Scopus 2024 per tanggal 30 September 2024 (820 artikel)

Adiwinata R.; Tandarto K.; Tanadi C.; Waleleng B.J.; Haroen H.; Rotty L.; Gosal F.; Rotty L.; Hendratta C.; Lasut P.; Winarta J.; Waleleng A.; Simadibrata P.; Simadibrata M.
Adiwinata, Randy (57190987165); Tandarto, Kevin (57450588500); Tanadi, Caroline (57218858365); Waleleng, Bradley Jimmy (57218497570); Haroen, Harlinda (55257490600); Rotty, Linda (55257626400); Gosal, Fandy (57218498488); Rotty, Luciana (57310038200); Hendratta, Cecilia (57224220648); Lasut, Pearla (57224216705); Winarta, Jeanne (57218497057); Waleleng, Andrew (57218497568); Simadibrata, Paulus (58742428800); Simadibrata, Marcellus (23499598400)
57190987165; 57450588500; 57218858365; 57218497570; 55257490600; 55257626400; 57218498488; 57310038200; 57224220648; 57224216705; 57218497057; 57218497568; 58742428800; 23499598400
Immune checkpoint inhibitor colitis, a rising issue in targeted cancer therapy era: A literature review
2024
Romanian journal of internal medicine = Revue roumaine de medecine interne
62
3
219
230
11
0
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85202790460&doi=10.2478%2frjim-2024-0015&partnerID=40&md5=53ab28fce4c0e360cb016f56501fc4cc
Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi "Prof. dr. R. D. Kandou" Hospital, Manado, Indonesia; MRCCC Siloam Hospital Semanggi, 2Gastrointestinal Cancer Center, Jakarta, Indonesia; 3Intensive Care Unit, Columbia Asia Hospital, Semarang, Indonesia; St. Carolus Hospital, Jakarta, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi "Prof. dr. R. D. Kandou" Hospital, Manado, Indonesia; 6Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; 7Abdi Waluyo Hospital, Jakarta, Indonesia; 8Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Adiwinata R., Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi "Prof. dr. R. D. Kandou" Hospital, Manado, Indonesia, MRCCC Siloam Hospital Semanggi, 2Gastrointestinal Cancer Center, Jakarta, Indonesia; Tandarto K., 3Intensive Care Unit, Columbia Asia Hospital, Semarang, Indonesia; Tanadi C., St. Carolus Hospital, Jakarta, Indonesia; Waleleng B.J., Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi "Prof. dr. R. D. Kandou" Hospital, Manado, Indonesia; Haroen H., 6Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Rotty L., 6Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Gosal F., Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi "Prof. dr. R. D. Kandou" Hospital, Manado, Indonesia; Rotty L., Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi "Prof. dr. R. D. Kandou" Hospital, Manado, Indonesia; Hendratta C., 6Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Lasut P., 6Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Winarta J., Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi "Prof. dr. R. D. Kandou" Hospital, Manado, Indonesia; Waleleng A., Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi "Prof. dr. R. D. Kandou" Hospital, Manado, Indonesia; Simadibrata P., MRCCC Siloam Hospital Semanggi, 2Gastrointestinal Cancer Center, Jakarta, Indonesia, 7Abdi Waluyo Hospital, Jakarta, Indonesia; Simadibrata M., 8Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Research advances in the oncology treatment field have led to the widespread use of immunotherapy. The usage of immune checkpoint inhibitor (ICI) has improved the survival of cancer patients with metastases. This has also led to the rapidly expanding indications for ICI use. However, ICI usage may lead to toxicity, which may be immune-related, in different organ-specific targets. The immune-related adverse events (irAEs) of ICI may lead to increased morbidity, decreased quality of life, and early termination of ICI. The clinical manifestations of irAEs in the gastrointestinal system are variable, ranging from self-limited to life-threatening or fatal events. In this review article, we would like to focus on discussing ICI-induced colitis, which is one of the most common ICI irAEs in the gastrointestinal tract. © 2024 Randy Adiwinata et al., published by Sciendo.
Colitis; Enterocolitis; Immune checkpoint inhibitors; Immunotherapy; Review
Colitis; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Neoplasms; immune checkpoint inhibitor; adverse event; colitis; drug therapy; human; immunology; immunotherapy; neoplasm
2501062X
38595047
Review

Unit Riset FKUI/Medical Research Unit
Gedung IMERI Tower Riset lt. 9, Jl. Salemba Raya No. 6, Jakarta Pusat, 10430
Telp. : +62 21 29189160 (ext. 201912)
E-mail : manajer.riset.fkui1@gmail.com